Literature DB >> 12421928

Lack of effector cell function and altered tetramer binding of tumor-infiltrating lymphocytes.

Ulrike Blohm1, Evelyn Roth, Kathrin Brommer, Tilman Dumrese, Felicia M Rosenthal, Hanspeter Pircher.   

Abstract

Tumor-specific CD8 T cell responses to MCA102 fibrosarcoma cells expressing the cytotoxic T cell epitope gp33 from lymphocytic choriomeningitis virus were studied. MCA102(gp33) tumors grew progressively in C57BL/6 mice, despite induction of peripheral gp33-tetramer(+) T cells that were capable of mediating antiviral protection, specific cell rejection, and concomitant tumor immunity. MCA102(gp33) tumors were infiltrated with a high number ( approximately 20%) of CD11b(+)CD11c(-) macrophage-phenotype cells that were able to cross-present the gp33 epitope to T cells. Tumor-infiltrating CD8 T cells exhibited a highly activated phenotype but lacked effector cell function. Strikingly, a significant portion of tumor-infiltrating lymphocytes expressed TCRs specific for gp33 but bound MHC tetramers only after cell purification and a 24-h resting period in vitro. The phenomenon of "tetramer-negative T cells" was not restricted to tumor-infiltrating lymphocytes from MCA102(gp33) tumors, but was also observed when Ag-specific T cells derived from an environment with high Ag load were analyzed ex vivo. Thus, using a novel tumor model, allowing us to trace tumor-specific T cells at the single cell level in vivo, we demonstrate that the tumor microenvironment is able to alter the functional activity of T cells infiltrating the tumor mass.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12421928     DOI: 10.4049/jimmunol.169.10.5522

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

1.  Lysophosphatidic acid inhibits CD8 T cell activation and control of tumor progression.

Authors:  Shannon K Oda; Pamela Strauch; Yuko Fujiwara; Amin Al-Shami; Tamas Oravecz; Gabor Tigyi; Roberta Pelanda; Raul M Torres
Journal:  Cancer Immunol Res       Date:  2013-10       Impact factor: 11.151

Review 2.  Immune surveillance of tumors.

Authors:  Jeremy B Swann; Mark J Smyth
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

Review 3.  Human CD8+ T-regulatory cells with low-avidity T-cell receptor specific for minor histocompatibility antigens.

Authors:  William J Burlingham; Els Goulmy
Journal:  Hum Immunol       Date:  2008-09-21       Impact factor: 2.850

4.  The innate immune system recognizes and regulates major histocompatibility complex class I (MHCI) expression on MHCIlow tumor cells.

Authors:  Bent Rubin; Joëlle Riond; Laetitia Courtiade; Nicolas Roullet; Jean-Edouard Gairin
Journal:  Cancer Immun       Date:  2008-09-11

Review 5.  Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication.

Authors:  Sergio A Quezada; Karl S Peggs; Tyler R Simpson; James P Allison
Journal:  Immunol Rev       Date:  2011-05       Impact factor: 12.988

6.  Increased Peptide Contacts Govern High Affinity Binding of a Modified TCR Whilst Maintaining a Native pMHC Docking Mode.

Authors:  David K Cole; Malkit Sami; Daniel R Scott; Pierre J Rizkallah; Oleg Y Borbulevych; Penio T Todorov; Ruth K Moysey; Bent K Jakobsen; Jonathan M Boulter; Brian M Baker
Journal:  Front Immunol       Date:  2013-06-26       Impact factor: 7.561

7.  CpG-matured murine plasmacytoid dendritic cells are capable of in vivo priming of functional CD8 T cell responses to endogenous but not exogenous antigens.

Authors:  Mariolina Salio; Michael J Palmowski; Ann Atzberger; Ian F Hermans; Vincenzo Cerundolo
Journal:  J Exp Med       Date:  2004-02-16       Impact factor: 14.307

Review 8.  Mechanisms of Metastatic Tumor Dormancy.

Authors:  Mary Osisami; Evan T Keller
Journal:  J Clin Med       Date:  2013-09-23       Impact factor: 4.241

9.  Tumor-altered dendritic cell function: implications for anti-tumor immunity.

Authors:  Kristian M Hargadon
Journal:  Front Immunol       Date:  2013-07-11       Impact factor: 7.561

10.  Endogenous tumor-reactive CD8+ T cells are differentiated effector cells expressing high levels of CD11a and PD-1 but are unable to control tumor growth.

Authors:  Xin Liu; Rachel M Gibbons; Susan M Harrington; Christopher J Krco; Svetomir N Markovic; Eugene D Kwon; Haidong Dong
Journal:  Oncoimmunology       Date:  2013-06-06       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.